LONDON, ON, January 6, 2009– KGK Synergize Inc. (“KGK”), a product development and contract research organization, today announced that it has received self affirmed GRAS (Generally Recognized as Safe) status for their flagship product, Sytrinol. An independent panel of experts assembled by AIBMR Life Sciences, reviewed the product’s profile for safety, and approved its self-affirmed status. Sytrinol, a proprietary ingredient clinically proven to improve cholesterol levels, can now be safely added to food and beverage products.
According to Najla Guthrie, President, “KGK has been working with numerous companies over the past few years to perfect the process of adding this ingredient to beverages, shakes, bars and even chocolate, without having solubility problems or the bitter taste of orange peel, the source of one of the components in the formulation”. Guthrie adds, “Sytrinol offers a new solution to food and beverage manufacturers who are interested in a patent protected heart healthy ingredient that is unlike the many others that are currently being used.”
Sytrinol, as of January 1, 2009, is now globally available through Proprietary Nutritionals, Inc.
About Sytrinol:
A proprietary patented composition, Sytrinol is a clinically proven ingredient composed of polymethoxylated flavones (PMF) and tocotrienols specially formulated for the prevention of atherosclerosis and hypercholesterolemia. For sales and distribution information, please contact:
Dean Mosca
Proprietary Nutritionals Inc.
Tel: (519) 647-2071
dean@pnibrands.com
Proprietary Nutritionals, Inc., a subsidiary of Pharmachem Laboratories, Inc markets a variety of patented, scientifically proven, branded ingredients to the nutrition industry, including Sytrinol, Benexia Chia Seed, Celadrin Joint Flexibility & Relief, Perluxan and the Berry-Max line of potent berry concentrates, including Cran-Max, Blue-Max, Bil-Max, Elder-Max, Cherry-Max, and Pom-Max.
About KGK Synergize Inc:
KGK provides contract research services to the health nutrition, biotechnology and pharmaceutical industries. These services include both pre-clinical and human clinical trials.
In addition to its contract research capabilities, KGK has a Product Development Division which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol for cardiovascular health, DiabetinolTM for the treatment and/or prevention of Type II Diabetes, and DermytolTM, a new product for the protection of sun damage to the skin.
